FDA

News

Roche eyes October decision by FDA for wet AMD implant

The FDA has started a review of a new implant version of Roche's ranibizumab therapy for wet age-related macular degeneration, that could offer patients with the sight-robbing disorder an a

News

Consumer group seeks resignation of top FDA staffers over Ad...

With the first patient set to receive Biogen's new Alzheimer's drug Aduhelm in Rhode Island today, US consumer advocacy organisation Public Citizen is deeply unhappy about the FDA's approva

News

Novavax unveils phase 3 COVID jab data, but has it missed th...

The top-line phase 3 data for Novavax' COVID-19 vaccine look good, with a 90% overall efficacy rate, but a dip in its share price indicates investors fear it could be too late for the progr

News

J&J must ditch 60m COVID jabs made at US plant, but 10m are ...

The failings at a Baltimore, US factory making Johnson & Johnson's COVID-19 vaccine mean that millions of doses of the shot will have to be jettisoned, according to an FDA update.

News

Ocugen gets a black eye as FDA denies emergency OK for COVID...

Ocugen is the first company to be affected by the FDA's recent decision to raise the bar on emergency use authorisations for COVID-19 medicines, and will have to file for full approval of i

News

Closeup of X-ray photography of human brain

And then there were three: another FDA adcomm member quits o...

The fallout over the FDA's decision to approved Biogen's Alzheimer's therapy Aduhelm continues to be felt, with a third member of its advisory committee resigning in protest.

Roche eyes October decision by FDA for wet AMD implant

Consumer group seeks resignation of top FDA staffers over Ad...

Novavax unveils phase 3 COVID jab data, but has it missed th...

J&J must ditch 60m COVID jabs made at US plant, but 10m are ...

Ocugen gets a black eye as FDA denies emergency OK for COVID...

And then there were three: another FDA adcomm member quits o...

Third Rock in $2bn drug-hunting pact with China's Funnel

Securing your ROI: Turning post-acquisition integration into...

FDA

Editor's Picks